Chemours (NYSE: CC) reported Q4 EPS of $1.05, $0.06 better than the analyst estimate of $0.99. Revenue for the quarter came in at $1.5 billion versus the consensus estimate of $1.51 billion.

The company expects to deliver 2019 Adjusted EBITDA within a range of $1.35 to $1.6 billion. Capital expenditures are expected to be approximately $500 million, with Free Cash Flow of greater than $550 million. The company expects Adjusted EPS of between approximately $4.00 and $5.05 per share.

(Street sees FY EPS of $5.57)

For earnings history and earnings-related data on Chemours (CC) click here.